Recombinant human interferon-like proteins

Details Recombinant human interferon-like proteins Recombinant human interferon-like proteins

2011-01-11

2011-01-11

Spector, Lorraine (Department: 1647)

Drug, bio-affecting and body treating compositions

Lymphokine

Interferon

C435S069510, C530S351000, C536S023520

Reexamination Certificate

active

07867482

ABSTRACT:
This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.

REFERENCES:
patent: 3699222 (1972-10-01), Isaacs et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4496689 (1985-01-01), Mitra
patent: 4640835 (1987-02-01), Shimizu et al.
patent: 4791192 (1988-12-01), Nakagawa et al.
patent: 4885166 (1989-12-01), Meyer et al.
patent: 4914033 (1990-04-01), Bell et al.
patent: 5055289 (1991-10-01), Frincke et al.
patent: 5071761 (1991-12-01), Meyer et al.
patent: 5137720 (1992-08-01), Gangemi et al.
patent: 5605793 (1997-02-01), Stemmer
patent: 5681811 (1997-10-01), Ekwuribe
patent: 5711944 (1998-01-01), Gilbert et al.
patent: 5738846 (1998-04-01), Greenwald et al.
patent: 5908626 (1999-06-01), Chang et al.
patent: 6174708 (2001-01-01), Sodoyer et al.
patent: 6174996 (2001-01-01), Johnson et al.
patent: 6514729 (2003-02-01), Bentzien
patent: 6531122 (2003-03-01), Pedersen et al.
patent: 6569420 (2003-05-01), Chen et al.
patent: 6685933 (2004-02-01), Zoon et al.
patent: 6946296 (2005-09-01), Patten et al.
patent: 7498152 (2009-03-01), Patten et al.
patent: 7625555 (2009-12-01), Wang
patent: 2003/0175241 (2003-09-01), Pedersen et al.
patent: 2004/0002474 (2004-01-01), Heinrichs et al.
patent: 2004/0013644 (2004-01-01), Rasmussen et al.
patent: 2004/0203118 (2004-10-01), Escary
patent: 2005/0201982 (2005-09-01), Hazel et al.
patent: 2005/0249703 (2005-11-01), Jensen
patent: 2006/0051859 (2006-03-01), Fu et al.
patent: 2007/0025966 (2007-02-01), Patten et al.
patent: 2007/0254838 (2007-11-01), Gantier et al.
patent: 2010/0099612 (2010-04-01), Wang
patent: 1431018 (2003-07-01), None
patent: 0115736 (2001-03-01), None
patent: 0125438 (2001-04-01), None
patent: 0136001 (2001-05-01), None
patent: 0172993 (2001-10-01), None
patent: 0236627 (2002-05-01), None
patent: 0236628 (2002-05-01), None
patent: 02036627 (2002-05-01), None
patent: 02074806 (2002-09-01), None
patent: 02081507 (2002-10-01), None
patent: 02095067 (2002-11-01), None
patent: 03002152 (2003-01-01), None
patent: 03075944 (2003-09-01), None
patent: 2004005341 (2004-01-01), None
patent: 2004020468 (2004-03-01), None
patent: 2004046365 (2004-06-01), None
patent: 2005023290 (2005-06-01), None
patent: 2005113592 (2005-12-01), None
patent: 2006020580 (2006-02-01), None
patent: 2007044083 (2007-04-01), None
patent: WO/2007/044083 (2007-04-01), None
patent: 2008154719 (2008-12-01), None
Jonasch et al., Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities, The Oncologist, 6, 34-55, 2001.
Brideau-Anderson, Amy D. et al., Directed Evolution of Gene-shuffled IFN—Molecules With Activity Profiles Tailored for Treatment of Chronic Viral Diseases, PNAS, vol. 104, No. 20, 2007, 8269-8274, May 15, 2007.
Folkman J. Successful treatment of an angiogenic disease. N Engl J Med. 1989; 320:1211-1212.
Clifford JL, et al. Retinoids and interferons as antiangiogenic cancer drugs. In: Teicher BA, ed. Antiangiogenic Agents in Cancer Therapy. Totowa, NJ: Humana Press Inc; 1999; 355-370.
Kaban LB, et al. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics. 1999; 103:1145-1149.
Sleijfer S, et al. Side effects of interferon-alpha therapy. Pharm World Sci. 2005; 27(6):423-431.
Streuli M, et al. Target cell specificity of two species derived from them. Proc Natl Acad Sci USA. 1981; 78(5): 2848-2852.
Raj, NB, et al. Synthesis, antiviral activity, and conformational characterization of mouse-human a-interferon hybrids. J Biol Chem. 1988; 263(18):8943-8952.
Mark DF, et al. Site-specific mutagenesis of the human fibroblast interferon gene. Proc Natl Acad Sci USA 1984; 81 (18): 5662-5666.
Chang CC, et al. Evolution of a cytokine using DNA family shuffling. Nat Biotechnol. 1999; 17(8):793-797.
Blatt LM, et al. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J interferon cytokine Res. 1996; 16:489-499.
Bowie JU, et al. Deciphering the Message in Protein Sequences: Tolerance to Amino acid Substitutions. Science 1990; 247(4948):1306-1310.
Creighton TE. Posttranslational covalent modification of polypeptide chains. In Proteins: Structure and Molecular Properties. Ed by Creighton TE. W. H. Freeman & Co. 1993; pp. 78-99. San Francisco, US.
Aplin JD and Wriston JC Jr. Preparation, properties, and applications of carbohydrate conjugates of proteins and lipids. CRC Crit Rev Biochem. 1981; 10(4):259-306.
Edge AS, et al. Deglycosylation of glycoproteins by trifluoromethanesulfonic acid. Anal Biochem. 1981; 118 (1):131-137.
Thotakura NP and Bohl OP. Enzymatic deglycosylation of glycoproteins. Meth Enzymol.1987; 138:350-359.
Field J, et al. Purification of a RAS-responsive adenylyl cyclase complex fromSaccharomyces cerevisiaeby use of an epitope addition method. Mol Cell Biol. 1988; 8(5):2159-2165.
Evan GI, et al. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol. 1985; 5(12):3610-3616.
Paborsky LR, et al. Mammalian cell transient expression of tissue factor for the production of antigen. Protein Eng. 1990; 3(6):547-553.
Einhauer A and Jungbauer A. The FLAG peptide, a versatile fusion tag for the purification of recombinant proteins. J Biochem Biophys Methods. 2001; 49(1-3):455-465.
Skinner H, et al. Use of the Glu-Glu-Phe C-terminal epitope for rapid purification of the catalytic domain of normal and mutant ras GTPase-activating proteins. J Biol Chem. 1991; 266(22):14163-14166.
Lutz-Freyermuth C, et al. Quantitative determination that one of two potential RNA-binding domains of the A protein component of the U1 small nuclear ribonucleoprotein complex binds with high affinity to stem-loop II of U1 RNA. Proc Natl Acad Sci USA. 1990; 87(16):6393-6397.
Zhang ZQ, et al. Construction and application of a high level expression vector containing PRPL promoter. Chinese J of Virol. 1990; 2:18-23.
McNeill TA. Interferon assay. J Immunol Methods. 1981; 46(2):121-127.
Rubinstein S, et al. Convenient assay for interferons. J. Virol. 1981; 37: 755-758.
Horisberger MA and de Staritzky K. A recombinant human interferon-α B/D hybrid with a broad host-range. J Gen Virol. 1987; 68:945-948.
Stitz L and Schellekens H. Influence of input multiplicity of infection on the antiviral activity of interferon. J Gen Virol. 1980; 46:205-210.
Yeo EY, et al. Effect of short-term ethanol on the proliferative response of Swiss 3T3 cells to mitogenic growth factors, Exp Mol Med. 2000: 32: 161-169.
Vignesh RC, et al. Effect of ethanol on human osteosarcoma cell proliferation, differentiation and mineralization. Toxicology. 2006; 220(1):63-70.
Cavanaugh PF Jr, et al. A semi-automated neutral red based chemosensitivity assay for drug screening. Investigational New Drugs. 1990; 8(4):347-354.
Raines EW and Ross R. Purification of human platelet-derived growth factor. Methods Enzymol. 1985; 109:749-773.
Wahl AF, et al. Gene expression of human DNA polymerase alpha during cell proliferation and the cell cycle. Mol Cell Biol. 1988; 8(11):5016-5025.
Cook JA and Mitchel JB. Viability measurements in mammalian cell systems. Anal Biochem. 1989; 179(1):1-7.
Porstmann T, et al. Quantitation of 5-bromo-2-deoxyuridine incorporation into DNA: an enzyme immunoassay for the assessment of th

Affiliated with

Also associated with

Rating

Recombinant human interferon-like proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant human interferon-like proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant human interferon-like proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2663137